Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug.
Their research, published today in the journal Molecular Pharmaceutics, shows how a new anti-heroin formulation that is safe in animal models remains stable at room temperature for at least 30 days. As a result, the vaccine is close to being ready for human testing.
“The heroin vaccine is one step closer to clinical evaluation,” says Candy S. Hwang, PhD, first author of the study and a research associate at TSRI.
According to the National Institute on Drug Abuse, 15,446 Americans died from heroin overdose between 2000 and 2016, and the mortality rates are increasing. Heroin abuse has been further fueled by a rise in prescription opioid abuse—studies show that opioid pain reliever users are 40 times more likely to abuse heroin.
The first formulation of the heroin vaccine was developed in 2013 by a team led by Kim D. Janda, PhD, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. It has been shown to be effective—and safe—in both mouse and non-human primate models.
The vaccine works by training the immune system antibodies to recognize and bind to heroin molecules, blocking the drug from reaching the brain to cause a “high.” Researchers believe that blocking the high of heroin will help eliminate the motivation for many recovering addicts to relapse into drug use.
The heroin molecule does not naturally prompt an antibody response, so researchers attach it to a carrier protein that alerts the immune system to start making antibodies. Scientists also add an ingredient called an adjuvant to the vaccine, which boosts the immune response and makes the vaccine more effective.
Hwang says, “Our goal was to prepare a vaccine that could be advanced to clinical trials. As such, we were looking for the best combination of ‘hapten’ (the heroin molecule), carrier protein and adjuvant to keep the vaccine both stable for transport and storage but still efficacious.”
For the new study, the researchers investigated how 20 different carrier protein/adjuvant combinations worked, including shelf stability based on temperature and storage time and whether the formulation was a liquid or powder.
Their experiments in rodent models showed that the best vaccine formulation contained a carrier protein called tetanus toxoid (TT) and adjuvants called alum and CpG ODN. The discovery that alum worked best as an adjuvant was especially significant since alum is one of the few adjuvants used in vaccines already approved by the U.S. Food and Drug Administration. The researchers also found that there was no difference in how well it worked between the liquid and powder versions of this formulation.
Hwang notes that the best vaccine formulation showed protection against lethal doses of heroin. This is particularly important as many heroin addicts have succumb to overdose and death during their attempts to quit the drug.
With this new study, the researchers have shown that the vaccine is safe and effective in animal models, stable under clinical conditions and reliant on an already-approved adjuvant. The next step is to find a producer to make the vaccine on a large scale.
“We believe that a heroin vaccine would be tremendously beneficial for people who have a heroin substance use disorder but have found difficulty in trying to quit,” says Hwang.
Learn more: Heroin vaccine blocks lethal overdose
The Latest on: Heroin vaccine
- UTMB Zika vaccine shows promise against aggressive brain cancer on September 19, 2018 at 10:00 pm
The vaccine has previously been shown to be effective in animal ... You just don’t know how the drug will interact with human tissue.” Though the study only showed a benefit from Zika’s destruction of ... […]
- Zika vaccine could be key to treat brain cancer, UTMB says on September 18, 2018 at 7:51 pm
Researchers at University of Texas Medical Branch at Galveston have been using the Zika vaccine to kill the brain cancer known as glioblastoma. It's a deadly cancer that is hard to target. […]
- UTMB: Zika vaccine shows promise in fight against brain cancer on September 18, 2018 at 1:14 pm
GALVESTON — A vaccine meant to destroy the Zika virus is showing promise in the fight against the deadliest form of brain cancer, according to researchers at The University of Texas Medical Branch at ... […]
- UTMB adapts Zika vaccine to fight brain cancer on September 18, 2018 at 11:49 am
GALVESTON, Texas - Researchers at The University of Texas Medical Branch at Galveston have successfully harnessed a Zika virus vaccine under development to target and kill the brain cancer known as gl... […]
- Potential Analysis of Ebola drug and Vaccines Market is Expected to Reach $56 million by 2020 on September 18, 2018 at 12:58 am
The new report by Allied Market Research titled, "Potential Analysis of Ebola drug and Vaccines Market - Global Opportunity Analysis and Industry Forecast to 2020" anticipates that the Ebola Virus Dis... […]
- Health regulator withholding vaccines results making it impossible to establish if drugs could be harmful on September 15, 2018 at 12:05 pm
Hundreds of children took part in three potentially risky Government drug trials, but Public Health England (PHE ... at random to try a new meningococcal and whooping cough booster vaccine. While dang... […]
- Locals plead for Hepatitis B drug on September 13, 2018 at 2:00 pm
The county government is yet to procure hepatitis B vaccines despite a rise in reported cases. Residents in disease-prone areas said they had requested the drugs but the health department had not comm... […]
- The adjuvant GLA-AF enhances human intradermal vaccine responses on September 12, 2018 at 11:45 am
1 Infectious Diseases Research Institute, Seattle, WA 98102, USA. 2 PAI Life Sciences Inc., Seattle, WA 98102, USA. 3 NanoPass Technologies Ltd., Nes Ziona, Israel. 4 Defense Advanced Research Project... […]
- China’s drug regulator clears 45 vaccine firms of safety issues on September 7, 2018 at 6:23 am
All 45 Chinese vaccine manufacturers showed no quality or safety issues during the drug regulator's recent inspection, the China Food and Drug Administration announced Friday. The administration sent ... […]
- China drug safety body finds no problems in inspections of vaccine makers on September 7, 2018 at 6:04 am
BEIJING (Reuters) - China’s drug safety body has found no problems in its inspection of 45 vaccine makers and will step up supervision of vaccine quality, it said on Friday, following a scandal ... […]
via Google News and Bing News